U.S. stock market closing | The 'Triple Witching Day' saw violent fluctuations in the final trading hour, with the Dow hitting a new all-time high; Intel surged in the final hour, gold reached a new high, and the offshore RMB rose by 300 points.
The Dow Jones hit a new high, while small-cap index fell more than 1% after seven consecutive gains, and the S&P briefly stopped falling in late trading. The Dow rose 1.6% for the week, the Nasdaq rose 1.5%, and energy stocks drove the S&P up 1.4%, the fifth consecutive weekly gain in six weeks, with small-cap stocks rising more than 2% and China concept stocks rising nearly 4% for the week.
Novo-Nordisk (NVO.US) GIP/GLP-1 dual receptor agonist clinical application in China.
The latest announcement on the official website of China's National Medical Products Administration pharmaceutical evaluation center shows that novo-nordisk a/s class 1 new drug NNC0519-0130 injection clinical trial application has been accepted.
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
BMO Capital analyst Evan Seigerman maintains $Novo-Nordisk A/S(NVO.US)$ with a buy rating, and maintains the target price at $160.According to TipRanks data, the analyst has a success rate of 54.1%
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155
TD Cowen analyst Michael Nedelcovych maintains $Novo-Nordisk A/S(NVO.US)$ with a buy rating, and sets the target price at $155.According to TipRanks data, the analyst has a success rate of 73.3% and
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Sector Update: Health Care Stocks Softer Friday Afternoon
Viking, Structure, Terns Benefitting From Disappointing Novo Nordisk Weight Loss Data
'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk
Novo Nordisk Shares Are Trading Lower. The Company Reported Results From Its Phase 2a Trial of Monlunabant in Obesity.
FTC Sues Units Of CVS Health , Cigna , And UnitedHealth For Allegedly Artificially Inflating Insulin Prices; FTC Case Does Not Name Insulin Drugmakers Eli Lilly, Novo Nordisk, And Sanofi , But Agency Reserves Right To Sue Later
Novo Nordisk's stock price plummeted nearly 6%! The trial results of oral weight-loss drugs are mixed with joy and sorrow.
①Compared with placebo, monlunabant has a significant statistically weight loss. However, the additional weight loss effect is limited in the higher dose group; ②Based on the research results, Novo-Nordisk a/s is expected to initiate a larger scale obesity phase 2b trial in 2025.
European Equities Traded in the US as American Depositary Receipts Decrease Friday
Novo Nordisk Stock Falls Over Oral Weight-loss Drug Data
Lilly Asks People Who Took Compounded Tirzepatide for Their Medical Records
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Experimental Obesity Pill Achieved Limited Extra Weight-Loss at Higher Doses
Novo Nordisk Says Further Work Needed to Balance Monlunabant's Efficacy, Safety in Obesity
Novo Nordisk's Monlunabant Shows Significant Weight Loss Results in Mid-stage Trial